Nancy Thornberry
CIK: 0001797826
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (9 total)
- Sep 2, 2026DNLI
Denali Therapeutics Inc.
Sale(S)Direct615 shares at avg. $23.74$15K - Sep 2, 2026DNLI
Denali Therapeutics Inc.
Sale(S)Direct10.8K shares at avg. $22.85$247K - Jun 22, 2026SDGR
Schrodinger, Inc.
Award(A)Direct8.1K shares- - Jun 3, 2026DNLI
Denali Therapeutics Inc.
Award(A)Direct6.4K shares- - May 1, 2026VRTX
VERTEX PHARMACEUTICALS INC / MA
Disposition(D)Direct398 shares- - May 1, 2026VRTX
VERTEX PHARMACEUTICALS INC / MA
Award(A)Direct472 shares- - Jun 18, 2025SDGR
Schrodinger, Inc.
Award(A)Direct6K shares- - Jun 3, 2025DNLI
Denali Therapeutics Inc.
Award(A)Direct6K shares- - May 1, 2025VRTX
VERTEX PHARMACEUTICALS INC / MA
Award(A)Direct398 shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 2, 2026 |  DNLI Denali Therapeutics Inc. | Sale(S) | 615 | $23.74 | $14,600 | Direct |
| Sep 2, 2026 | DNLI Denali Therapeutics Inc. | Sale(S) | 10,824 | $22.85 | $247,328 | Direct |
| Jun 22, 2026 |  SDGR Schrodinger, Inc. | Award(A) | 8,141 | - | $0 | Direct |
| Jun 3, 2026 | DNLI Denali Therapeutics Inc. | Award(A) | 6,408 | - | $0 | Direct |
| May 1, 2026 |  VRTX VERTEX PHARMACEUTICALS INC / MA | Disposition(D) | 398 | - | $0 | Direct |
| May 1, 2026 | VRTX VERTEX PHARMACEUTICALS INC / MA | Award(A) | 472 | - | $0 | Direct |
| Jun 18, 2025 | SDGR Schrodinger, Inc. | Award(A) | 5,997 | - | - | Direct |
| Jun 3, 2025 | DNLI Denali Therapeutics Inc. | Award(A) | 6,037 | - | - | Direct |
| May 1, 2025 | VRTX VERTEX PHARMACEUTICALS INC / MA | Award(A) | 398 | - | - | Direct |
1-9 of 9 transactions
About Thornberry Nancy
Thornberry Nancy (SEC CIK 0001797826) files insider reports with the SEC as Director of Denali Therapeutics Inc. (DNLI), Director of Schrodinger, Inc. (SDGR) and Director of VERTEX PHARMACEUTICALS INC / MA (VRTX).
Signal8 holds 7 ownership filings by Thornberry Nancy, all Form 4s, filed between May 5, 2025 and Sep 4, 2026. Those filings report 9 transactions, from May 1, 2025 to Sep 2, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Thornberry Nancy's filings is in SOUTH SAN FRANCISCO, CA.
Recent filings by Thornberry Nancy
- Sep 2, 2026: Open-market sales of DNLI shares (2 lines, Form 4, code S).
- Jun 22, 2026: Grant or award of SDGR shares (Form 4, code A).
- Jun 3, 2026: Grant or award of DNLI shares (Form 4, code A).
- May 1, 2026: Disposition to issuer transaction of VRTX shares (Form 4, code D).
- May 1, 2026: Grant or award of VRTX shares (Form 4, code A).
Other insiders filing for Denali Therapeutics Inc. (DNLI)
- Chin Peter Scott, Chief Medical Officer
- Schuth Alexander O., COFO and Secretary
- Watts Ryan J., President and CEO
- FLATLEY JAY T, Director
- Klein Peter S, Director
- Krognes Steve E., Director